Borderline Personality Disorder, Non-suicidal Self-injury (NSSI)
Conditions
Brief summary
The primary aim is to investigate the effectiveness of Emotion Regulation Group Therapy (ERGT) for women who self-harm in ordinary psychiatric outpatient health care.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* NSSI a minimum of three times in the last six months * Meets at least three criteria for Borderline Personality Disorder according to DSM-IV-TR * Contact with an other individual therapist, psychiatrist, case manager or equal
Exclusion criteria
* Insertion/withdrawal of psychopharmacological substances within two months prior to the treatment * Other acute primary axis I diagnosis (e.g. anorexia nervosa) that demand treatment in first hand * Bipolar disorder I or primary psychosis * Current substance dependence (the last month) * Current life circumstances that would hinder the treatment (i.e. ongoing domestic abuse) * Insufficient Swedish language skills * Cocurrent treatment with Mentalization based therapy (MBT) or Dialectical behavioral therapy (DBT)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of non-suicidal self-injury as measured by Deliberate Self-Harm Inventory (DSHI) | Baseline (from inclusion to treatment start), (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in deliberate self-harm after 14 weeks and at 6- and 12 months after treatment has ended. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P) | Baseline, post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in societal costs after 14 weeks and at 6- and 12 months after treatment has ended. |
| Euroqol-5D (EQ-5D) | Baseline, post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in quality of life after 14 weeks and at 6- and 12 months after treatment has ended. |
| Borderline Symptom List Behavior supplement (BSL-supplement) | Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks), and six and twelve months follow-up. | Change from Baseline in self-destructive behaviors after 14 weeks and at 6- and 12 months after treatment has ended. |
| Difficulties in Emotion Regulation Scale (DERS) | Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in difficulties with emotion regulation after 14 weeks and at 6- and 12 months after treatment has ended. |
| Sheehan Disability Scale (SDS) | Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in global functioning after 14 weeks and at 6- and 12 months after treatment has ended. |
| The Borderline Evaluation of Severity over Time (BEST). | Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in Borderline severity symptoms after 14 weeks and at 6- and 12 months after treatment has ended. |
| The Depression Anxiety Stress Scales (DASS) | Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in depression and anxiety after 14 weeks and at 6- and 12 months after treatment has ended. |
| Inventory of Interpersonal Problems - Borderline Personality Disorder (IIP-BPD) | Pre-treatment (7 days prior to treatment start), post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in interpersonal problems after 14 weeks and at 6- and 12 months after treatment has ended. |
| Diary questionnaire (DQ) | Baseline (from inclusion to treatment start), pre-treatment (7 days prior to treatment start), weekly (once a week following treatment start), post-treatment (14 weeks) and six and twelve months follow-up. | Change from Baseline in positive and negative affect after 14 weeks and at 6- and 12 months after treatment has ended. |
Countries
Sweden